96 research outputs found

    Stability of concentrated suspensions under Couette and Poiseuille flow

    Get PDF
    The stability of two-dimensional Poiseuille flow and plane Couette flow for concentrated suspensions is investigated. Linear stability analysis of the two-phase flow model for both flow geometries shows the existence of a convectively driven instability with increasing growth rates of the unstable modes as the particle volume fraction of the suspension increases. In addition it is shown that there exists a bound for the particle phase viscosity below which the two-phase flow model may become ill-posed as the particle phase approaches its maximum packing fraction. The case of two-dimensional Poiseuille flow gives rise to base state solutions that exhibit a jammed and unyielded region, due to shear-induced migration, as the maximum packing fraction is approached. The stability characteristics of the resulting Bingham-type flow is investigated and connections to the stability problem for the related classical Bingham-flow problem are discussed

    Stability of concentrated suspensions under Couette and Poiseuille flow

    Full text link
    The stability of two-dimensional Poiseuille flow and plane Couette flow for concentrated suspensions is investigated. Linear stability analysis of the two-phase flow model for both flow geometries shows the existence of a convectively driven instability with increasing growth rates of the unstable modes as the particle volume fraction of the suspension increases. In addition it is shown that there exists a bound for the particle phase viscosity below which the two-phase flow model may become ill-posed as the particle phase approaches its maximum packing fraction. The case of two-dimensional Poiseuille flow gives rise to base state solutions that exhibit a jammed and unyielded region, due to shear-induced migration, as the maximum packing fraction is approached. The stability characteristics of the resulting Bingham-type flow is investigated and connections to the stability problem for the related classical Bingham-flow problem are discussed

    Third generation autologous chondrocyte implantation is a good treatment option for athletic persons

    Get PDF
    PURPOSE Autologous chondrocyte implantation is an established method for the treatment of joint cartilage damage. However, to date it has not been established that autologous chondrocyte implantation is an appropriate procedure for cartilage defects therapy in athletic persons. The aim of this study is to analyze if third-generation autologous chondrocyte implantation is an appropriate treatment for athletic persons with full cartilage defect of the knee joints. METHODS A total of 84 patients were treated with third-generation autologous chondrocyte implantation (NOVOCART® 3D). The mean follow-up time was 8 years (5–14). Sports activity was measured via UCLA Activity Score and Tegner Activity Scale before the onset of knee pain and postoperatively in an annual clinical evaluation. 41 athletic persons and 43 non-athletic persons (UCLA-Cut-off: 7; Tegner Activity Scale-Cut-off: 4) were analyzed. Patient reported outcomes were captured using IKDC subjective, KOOS, Lysholm score and VAS score on movement. RESULTS Patient reported outcomes (IKDC, VAS at rest, VAS on movement) showed significant improvement (p < 0.001) postoperatively. Athletic persons demonstrated significantly better results than non-athletic persons in the analyzed outcome scores (IKDC: p < 0.01, KOOS: p < 0.01, Lysholm score: p < 0.01). 96.4% of the patients were able to return to sport and over 50% returned or surpassed their preinjury sports level. The remaining patients were downgraded by a median of two points on the UCLA- and 2.5 on the Tegner Activity Scale. A shift from high-impact sports to active events and moderate or mild activities was found. Furthermore, it was shown that preoperative UCLA score and Tegner Activity Scale correlated significantly with the patient reported outcome postoperatively. CONCLUSION Autologous chondrocyte implantation is a suitable treatment option for athletic persons with full-thickness cartilage defects in the knee. The return to sports activity is possible, but includes a shift from high-impact sports to less strenuous activities

    The influence of different footprint preparation techniques on tissue regeneration in rotator cuff repair in an animal model

    Get PDF
    Introduction: Rotator cuff tears are common diseases of the upper extremity. There are no recommendations to the surgeon on how to prepare the footprint to ensure optimal tendon-to-bone healing. However, biologic augmentation using stem cells and growth factors is considered to encourage the healing process of the tendon. The aim of the study was to investigate the biomechanical and histological outcome of different footprint preparations in rotator cuff repair. Material and methods: One hundred and eighty-nine Sprague-Dawley rats were randomly assigned to either spongialization, radiofrequency ablation or an untreated control group. Rats were killed after 1 or 7 weeks for histological evaluation or after 7 weeks for biomechanical testing. Results: Histological evaluation showed better tissue organization in the control and spongialization group compared to the radiofrequency ablation group. The highest collagen I to collagen III quotient was found in the control group, followed closely by the spongialization group. Measured quotients showed a decrease in the values after 1 week compared to the values after 7 weeks, except in the radiofrequency ablation group, where an increase was detected. A significant difference was found in the load to failure test comparing the radiofrequency ablation group to the spongialization group (p = 0.0409) and control group (p = 0.014), but not comparing the spongialization group to the control group (p = 0.2456). Conclusions: The results of this study suggest that spongialization of the footprint before attaching the torn supraspinatus tendon can lead to better structural properties and higher quality of tendon-to-bone restoration at the insertion area when compared with radiofrequency ablation

    Использование голосового интерфейса для взаимодействия пользователя с веб-сервисом

    Get PDF
    В статье рассмотрены виды существующих интерфейсов взаимодействия пользователя с ЭВМ, приводится сравнительный анализ характеристик интерфейсов. Подробно рассматривается голосовой интерфейс и его использование для взаимодействия пользователя с веб-сервисом

    Double-blind, placebo-controlled first in human study to investigate an oral vaccine aimed to elicit an immune reaction against the VEGF-Receptor 2 in patients with stage IV and locally advanced pancreatic cancer

    Get PDF
    BACKGROUND: The investigational oral DNA vaccine VXM01 targets the vascular endothelial growth factor receptor 2 (VEGFR-2) and uses Salmonella typhi Ty21a as a vector. The immune reaction elicited by VXM01 is expected to disrupt the tumor neovasculature and, consequently, inhibit tumor growth. VXM01 potentially combines the advantages of anti-angiogenic therapy and active immunotherapy. METHODS/DESIGN: This phase I trial examines the safety, tolerability, and immunological and clinical responses to VXM01. The randomized, placebo-controlled, double blind dose-escalation study includes up to 45 patients with locally advanced and stage IV pancreatic cancer. The patients will receive four doses of VXM01 or placebo in addition to gemcitabine as standard of care. Doses from 10(6) cfu up to 10(10) cfu of VXM01 will be evaluated in the study. An independent data safety monitoring board (DSMB) will be involved in the dose-escalation decisions. In addition to safety as primary endpoint, the VXM01-specific immune reaction, as well as clinical response parameters will be evaluated. DISCUSSION: The results of this study shall provide the first data regarding the safety and immunogenicity of the oral anti-VEGFR-2 vaccine VXM01 in cancer patients. They will also define the recommended dose for phase II and provide the basis for further clinical evaluation, which may also include additional cancer indications. TRIAL REGISTRATION: EudraCT No.: 2011-000222-29, NCT01486329, ISRCTN6880927
    corecore